Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04122001 · ClinicalTrials.gov registry record · NA

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

A NA study of Alzheimer Disease, Early Onset and Logopenic Progressive Aphasia, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT04122001 is a NA study of Alzheimer Disease, Early Onset and Logopenic Progressive Aphasia that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 1,480-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04122001, a NA study of Alzheimer Disease, Early Onset and Logopenic Progressive Aphasia, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating synaptic damage that correlates with cognitive decline in AD patients. Transcranial Direct Current Stimulation (tDCS) is a safe, non-invasive, non-painful electrical stimulation of the brain that is shown to act as a primer at the synaptic level when administered along with behavioral therapy, mostly involving language, learning and memory. Previous studies have shown that tDCS over the left angular gyrus (AG) improves language associative learning in the elderly through changes in functional connectivity between the AG and the hippocampus. The investigators' previous clinical trial on the effects of tDCS in neurodegenerative disorders has also shown augmented effects of lexical retrieval for tDCS. In the present study the investigators will compare the effects of active vs. sham tDCS over the AG-an area that is part of the default mode network but also a language area, particularly important for semantic integration and event processing-in two predominant AD variants: probable AD with amnesic phenotype (amnesic/typical AD) and probable AD with non-amnesic (language deficit) phenotype also described as logopenic variant PPA with AD pathology (aphasic/atypical AD). The investigators aim to: (1) determine whether active high-definition tDCS (HD-tDCS) targeting the left AG combined with a Word-List Learning Intervention (WordLLI) will improve verbal learning; (2) identify the changes in functional connectivity between the stimulated area (AG) and other structurally and functionally connected areas using resting-state functional magnetic resonance imaging; (3) identify changes in the inhibitory neurotransmitter GABA at the stimulation site using magnetic resonance spectroscopy. Furthermore, the investigators need to determine the characteristics o

Interventions

  • DEVICE Sham
  • DEVICE Active, in-person HD-tDCS or active remote tDCS
  • OTHER Word List Learning Intervention (WordLLI)

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2020-08-17
Est. Completion 2026-05-31
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT04122001

The ClinicalTrials.gov registry entry for NCT04122001 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,480-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (94% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Alzheimer Disease, Early Onset appearing as the primary indexed condition, and to 3 interventions - of which Sham is the first listed.

NCT04122001 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04122001 about?

NCT04122001 is a clinical study titled "Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease". Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating synaptic damage that correlates with cognitive decline in AD patients. Tr...

What is the current status of trial NCT04122001?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2020-08-17. Estimated completion is 2026-05-31.

What conditions does trial NCT04122001 study?

This clinical trial studies the following conditions: Alzheimer Disease, Early Onset, Logopenic Progressive Aphasia, Atypical Alzheimer's Disease.

What interventions are being tested in trial NCT04122001?

The interventions under investigation include: Sham (DEVICE), Active, in-person HD-tDCS or active remote tDCS (DEVICE), Word List Learning Intervention (WordLLI) (OTHER).

Who is sponsoring clinical trial NCT04122001?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04122001 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease, Early Onset

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.